Sutro Biopharma (STRO) Net Cash Flow Growth (1y) (2018 - 2025)

Sutro Biopharma (STRO) Net Cash Flow Growth (1y) (2018 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 172.72%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 53.21%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 75.60%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 1,421.76%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 149.49%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -100.75%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -104.22%
10 Sutro Biopharma 339.58 Mn 175.24 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -149.58%
Sep 30, 2025 -97.73%
Jun 30, 2025 -265.05%
Mar 31, 2025 -1,968.27%
Dec 31, 2024 225.15%
Sep 30, 2024 154.67%
Jun 30, 2024 -85.19%
Mar 31, 2024 -126.71%
Dec 31, 2023 74.63%
Sep 30, 2023 -967.65%
Jun 30, 2023 243.77%
Mar 31, 2023 1,105.82%
Dec 31, 2022 -16,802.73%
Sep 30, 2022 168.77%
Jun 30, 2022 8,648.08%
Mar 31, 2022 98.99%
Dec 31, 2021 -100.21%
Sep 30, 2021 -21,127.27%
Jun 30, 2021 -97.36%
Mar 31, 2021 -489.42%